Madrigal Pharmaceuticals's total inventories for the quarter that ended in Mar. 2026 was €96.9 Mil. Madrigal Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €80.4 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Madrigal Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €12.22.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Madrigal Pharmaceuticals's Days Inventory for the
three
months ended in Mar. 2026 was 316.02.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Madrigal Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.29.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Madrigal Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.30.
Madrigal Pharmaceuticals (MIL:1MDGL) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Madrigal Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Madrigal Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Madrigal Pharmaceuticals Total Inventories Related Terms
Madrigal Pharmaceuticals Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Madrigal Pharmaceuticals (MIL:1MDGL) has a Total Inventories of €96.9 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Madrigal Pharmaceuticals and its competitors.
Is Madrigal Pharmaceuticals' Total Inventories too high?
Madrigal Pharmaceuticals' current Total Inventories is €96.9 Mil. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Total Inventories compare to BMRN and ARWR?
Madrigal Pharmaceuticals' Total Inventories of €96.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Total Inventories is €96.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current Total Inventories of €96.9 Mil. The current Total Inventories is €96.9 Mil. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current Total Inventories is €96.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score
Get the complete analysis for MIL:1MDGL
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1MDGL has been successfully added to your 
